Application 215255
- Type
- ANDA
- Sponsor
- MACLEODS PHARMACEUTICALS LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | METFORMIN HYDROCHLORIDE; CANAGLIFLOZIN | TABLET, EXTENDED RELEASE | 1000MG | No | No |
| 002 | CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | METFORMIN HYDROCHLORIDE; CANAGLIFLOZIN | TABLET, EXTENDED RELEASE | 50MG | No | No |
| 003 | CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | METFORMIN HYDROCHLORIDE; CANAGLIFLOZIN | TABLET, EXTENDED RELEASE | 150MG | No | No |
| 004 | CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | METFORMIN HYDROCHLORIDE; CANAGLIFLOZIN | TABLET, EXTENDED RELEASE | 500MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.